LBIO (Longevity Biomedical) Total Current Assets: $0.00 Mil (As of . 20)


What is Longevity Biomedical Total Current Assets?

Longevity Biomedical LBIO Total Current Assets is $0.00 Mil as of . 20.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Longevity Biomedical's total current assets for the quarter that ended in . 20 was $0.00 Mil.

Longevity Biomedical  (NAS:LBIO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Longevity Biomedical's Liquidation Value for the quarter that ended in . 20 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=-+0.75 * +0.5 *
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Total Current Assets Related Terms

Longevity Biomedical Total Current Assets Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Total Current Assets Chart

Longevity Biomedical Annual Data
Trend
Total Current Assets

Longevity Biomedical Semi-Annual Data
Total Current Assets

Longevity Biomedical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Longevity Biomedical's Total Current Assets for the fiscal year that ended in . 20 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=+++
=0.00

Longevity Biomedical's Total Current Assets for the quarter that ended in . 20 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=+++
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $0.00 Mil mean?
Longevity Biomedical (LBIO) has a Total Current Assets of $0.00 Mil as of . 20. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Longevity Biomedical and its competitors.
Is Longevity Biomedical's Total Current Assets too high?
Longevity Biomedical's current Total Current Assets is $0.00 Mil.
How does Longevity Biomedical's Total Current Assets compare to ?
Longevity Biomedical's Total Current Assets of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Longevity Biomedical and its competitors. Longevity Biomedical's current Total Current Assets is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current Total Current Assets of $0.00 Mil. The current Total Current Assets is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current Total Current Assets is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.